Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 13 points (0.1%) at 17,581 as of Wednesday, Dec. 9, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,741 issues advancing vs. 1,197 declining with 165 unchanged.

The Health Services industry currently sits down 0.1% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the industry include Cooper Companies ( COO), down 2.1%, Opko Health ( OPK), down 2.0%, Grifols ( GRFS), down 1.7%, ResMed ( RMD), down 1.7% and DexCom ( DXCM), down 1.6%. Top gainers within the industry include Community Health Systems ( CYH), up 3.4%, Mednax ( MD), up 1.5%, Agilent Technologies ( A), up 0.8% and Alibaba Group ( BABA), up 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Laboratory Corp of America Hldgs ( LH) is one of the companies pushing the Health Services industry lower today. As of noon trading, Laboratory Corp of America Hldgs is down $1.34 (-1.1%) to $123.76 on light volume. Thus far, 239,381 shares of Laboratory Corp of America Hldgs exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $123.76-$125.70 after having opened the day at $124.99 as compared to the previous trading day's close of $125.10.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. Laboratory Corp of America Hldgs has a market cap of $12.6 billion and is part of the health care sector. Shares are up 15.9% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Laboratory Corp of America Hldgs a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Laboratory Corp of America Hldgs as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, good cash flow from operations, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Laboratory Corp of America Hldgs Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Becton Dickinson ( BDX) is down $0.87 (-0.6%) to $153.83 on average volume. Thus far, 430,931 shares of Becton Dickinson exchanged hands as compared to its average daily volume of 972,900 shares. The stock has ranged in price between $153.33-$155.53 after having opened the day at $153.33 as compared to the previous trading day's close of $154.70.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Becton, Dickinson and Company develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. Becton Dickinson has a market cap of $32.4 billion and is part of the health care sector. Shares are up 11.2% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Becton Dickinson a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Becton Dickinson as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, solid stock price performance, expanding profit margins and reasonable valuation levels. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Becton Dickinson Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Express Scripts ( ESRX) is down $0.45 (-0.5%) to $85.95 on light volume. Thus far, 1.0 million shares of Express Scripts exchanged hands as compared to its average daily volume of 4.3 million shares. The stock has ranged in price between $85.78-$87.00 after having opened the day at $85.79 as compared to the previous trading day's close of $86.40.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company operates through two segments, PBM and Other Business Operations. Express Scripts has a market cap of $58.4 billion and is part of the health care sector. Shares are up 2.0% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Express Scripts a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, increase in net income, good cash flow from operations, notable return on equity and solid stock price performance. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Express Scripts Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).